Buckley Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Buckley Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-5,000	Closed	-$212K	–	125
2020 Q1	$212K	Hold	5,000	–	–	0.12%	109
2019 Q4	$305K	Hold	5,000	–	–	0.14%	111
2019 Q3	$205K	Hold	5,000	–	–	0.1%	129
2019 Q2	$236K	Buy	+5,000	New	+$200K	0.11%	135
2018 Q4	–	Sell	-5,000	Closed	-$222K	–	141
2018 Q3	$222K	Buy	+5,000	New	+$262K	0.1%	146

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Buckley Wealth Management's CRSP Position: Q2 2020 in Review

Buckley Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q2 2020, closing a stake of 5,000 shares — an estimated $212K sold.

Buckley Wealth Management first reported a position in CRSP in Q3 2018 and held it in 5 quarters. The position peaked at $305K in Q4 2019. 276 funds tracked by Wall St. Rank hold CRSP as of Q2 2020.

Buckley Wealth Management reported no remaining CRISPR Therapeutics position as of Q2 2020 after selling out during the quarter.
Buckley Wealth Management sold 5,000 CRISPR Therapeutics shares in Q2 2020, an estimated $212K.
Buckley Wealth Management first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 5 quarters.
Buckley Wealth Management's CRISPR Therapeutics position peaked at $305K in Q4 2019.
276 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2020.

Based on Buckley Wealth Management's 13F filing for Q2 2020, filed 15 Jul 2020.